Treatment of Anemia of Critical Illness

Transfusion Strategy

The American Society of Anesthesiologists recommends transfusing at hemoglobin <70 g/L (7 g/dL) for most critically ill patients, including those with ARDS and septic shock 1, 2
A restrictive transfusion approach reduces mortality and morbidity compared to liberal transfusion strategies in critically ill patients 3
For patients with acute coronary syndromes or ischemic heart disease, consider a higher transfusion threshold of <80 g/L (8 g/dL) 1, 2
Transfuse one unit of packed red blood cells at a time, then reassess hemoglobin before deciding on additional units, as each unit increases hemoglobin by approximately 1 g/dL 4, 5, 6
Use red blood cells regardless of storage time, as there is no evidence that fresher blood improves outcomes 4, 5
Leuko-depleted blood is preferred when available, as it may reduce transfusion-related complications 3

Implement small-volume blood collection tubes to minimize diagnostic blood loss in critically ill patients 1, 4, 5, 6
Avoid standing orders for routine blood draws—order only necessary tests to reduce phlebotomy-related blood loss 1
Monitor hemoglobin weekly after initiating or adjusting therapy until stable, then at least monthly, as hemoglobin drops by a mean of 0.52 g/L per day in ICU patients 1, 2, 4, 5, 6

Consider erythropoietin treatment specifically in trauma patients without contraindications, as available evidence does not support routine use in general critically ill populations 4, 5, 6
Avoid routine iron therapy in critically ill patients except when administered concurrently with erythropoietin, and evaluate iron status before and during treatment 1, 2, 4, 5, 6

Anemia of critical illness is characterized by disturbed iron homeostasis, impaired erythropoiesis, reduced red cell survival, and blunted erythropoietin production, similar to anemia of chronic disease 1, 2, 3
Approximately 30-40% of critically ill patients develop moderately severe anemia (Hb <90 g/L) during their ICU stay, and more than half of patients anemic at ICU discharge remain anemic 6 months later 1, 2, 4, 5, 6

Recognize that RBC transfusion carries substantial risks, including increased infection, multi-organ failure, transfusion-related acute lung injury (TRALI), and transfusion-associated circulatory overload (TACO) 3
Never target hemoglobin levels >11 g/dL, as this increases mortality, stroke, myocardial infarction, and thromboembolism without improving outcomes 1, 2
In patients with hemoglobin <70 g/L with respiratory symptoms or hemodynamic instability, transfusion should not be delayed while awaiting diagnostic results, as this represents a life-threatening emergency 7, 8

Patients with solid organ and hematological malignancy often require blood components, but there is no agreed consensus on optimal transfusion threshold, and evidence in these groups is largely from single-center RCTs 1, 2
In active hemorrhage, do not attempt to normalize blood pressure—achieve a lower acceptable blood pressure with volume resuscitation alone, and implement major hemorrhage protocols for volume resuscitation during uncontrolled hemorrhage 1, 2

Anemia of acute infection is defined by inflammation‑induced low serum iron, impaired red‑cell production, reduced red‑cell lifespan, and a blunted erythropoietin response; management emphasizes treating the infection and using a restrictive transfusion trigger of hemoglobin < 7 g/dL in most patients【9】.
Pro‑inflammatory cytokines (e.g., TNF, IL‑1, IL‑6) directly suppress erythropoiesis and blunt the normal erythropoietin rise in response to low hemoglobin【9】.

Achieving complete control of the infectious process is the most effective intervention for correcting the anemia; specific anemia‑directed therapies are generally unnecessary【10】.
Clinical assessment of disease activity may not always parallel acute‑phase reactants such as C‑reactive protein, requiring vigilant evaluation beyond laboratory markers【10】.

Oral or intravenous iron does not improve anemia in this setting despite low serum iron, because iron is functionally sequestered rather than truly deficient【9】【11】.

A restrictive transfusion threshold of hemoglobin < 7 g/dL is recommended for stable patients without cardiovascular disease, as it reduces mortality, morbidity, and the risk of new infections compared with liberal thresholds【9】.
Transfusion‑related immunomodulation increases infection risk, and liberal transfusion (target > 10 g/dL) may paradoxically lower sepsis incidence only in select populations (e.g., acute brain injury), a finding that requires further validation【12】【13】.

Transfusion is linked to higher infection rates due to transfusion‑related immunomodulation【9】.
Serious adverse events include multi‑organ failure, transfusion‑related acute lung injury (TRALI), circulatory overload (TACO), and fluid overload with pulmonary edema【9】.
Use of leukoreduced blood products is advised when available, as they may lessen transfusion‑related complications【9】.

Routine use of erythropoietin is not supported in the general critically ill population and should be reserved for specific scenarios (e.g., trauma patients without contraindications)【9】.
Iron therapy should be avoided unless combined with erythropoietin in a setting where true iron deficiency is documented; otherwise it offers no benefit and may increase the risk of iron overload【11】.

When evaluating anemia, clinicians should rule out alternative etiologies such as malignancy, medication‑induced marrow suppression, or concurrent infections【10】.
Successful eradication of the infection remains the definitive treatment; anemia‑specific interventions serve only a supportive role【10】.